Biogen’s Top Commercial Exec, Kingsley, Steps Down

Xconomy Boston — 

Cambridge-based Biogen (NASDAQ: BIIB) said Friday that Tony Kinglsey, its head commercial executive, is leaving the company. John Cox, who heads Biogen’s pharmaceutical operations, is taking his place on an interim basis. The news comes amidst a tough time for Biogen, which has seen its share price slide more than 30 percent over the past few months. Kingsley is the second top Biogen executive to leave over that time—former R&D chief Doug Williams left to run a (still unnamed) cancer startup in July.